EQRx Past Earnings Performance
Past criteria checks 0/6
EQRx's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 17.4% annually.
Key information
-12.3%
Earnings growth rate
98.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -22.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely
Jul 25
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Feb 22We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate
Nov 08EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs
Aug 28 EQRx GAAP EPS of -$0.17 beats by $0.03
Aug 11Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation
Jul 24We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth
Apr 08EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Dec 24Revenue & Expenses Breakdown
How EQRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -260 | 104 | 204 |
| 30 Jun 23 | 0 | -263 | 114 | 240 |
| 31 Mar 23 | 0 | -272 | 124 | 244 |
| 31 Dec 22 | 0 | -169 | 129 | 227 |
| 30 Sep 22 | 0 | -146 | 138 | 211 |
| 30 Jun 22 | 0 | -100 | 121 | 179 |
| 31 Mar 22 | 0 | -53 | 102 | 153 |
| 31 Dec 21 | 0 | -100 | 80 | 116 |
| 30 Sep 21 | 0 | -279 | 50 | 229 |
| 30 Jun 21 | 0 | -296 | 40 | 256 |
| 31 Mar 21 | 0 | -269 | 32 | 237 |
| 31 Dec 20 | 0 | -250 | 27 | 223 |
Quality Earnings: EQRX is currently unprofitable.
Growing Profit Margin: EQRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EQRX is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare EQRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EQRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: EQRX has a negative Return on Equity (-22.23%), as it is currently unprofitable.